Q1 2026 Dr Reddy's Laboratories Ltd Earnings Call Transcript
Key Points
- Dr Reddy's Laboratories Ltd (RDY) reported a steady double-digit revenue growth, with consolidated revenues for the quarter at INR8,545 crores, reflecting an 11% year-over-year increase.
- The company achieved an EBITDA margin of 26.7%, surpassing their aspiration of 25%, driven by the inclusion of their consumer health care business.
- Dr Reddy's Laboratories Ltd (RDY) maintained a strong balance sheet with a net cash surplus of USD341 million as of June 30, 2025.
- The biosimilar business gained momentum through a strategic collaboration with Albotech for the co-development, manufacturing, and commercialization of pembrolizumab.
- The company launched 26 new products across multiple countries in the emerging markets segment, reinforcing their commitment to expanding access and market presence.
- The US generics business experienced softness, primarily due to price erosion in selected products, including lenalidomide.
- Consolidated gross profit margin decreased by 350 basis points year-on-year, largely due to price erosion in the generic segment and lower operating leverage.
- SG&A expenses increased by 13% year-over-year, driven by strategic growth-oriented investments, accounting for 30% of sales during the quarter.
- The R&D spend for the quarter was broadly flat year-over-year but declined by 14% sequentially, with expectations to remain in the range of 7% to 7.5% of sales for the full fiscal year.
- The US FDA issued Form 483 with observations for multiple facilities, indicating regulatory challenges that need to be addressed.
Hey, good day everyone, and welcome to the Q1 FI26 earnings call of Dr Reddy's Laboratories Limited. I'm Awaraithaam and I'm part of the Dr. Reddy's Investor Relations team. (Operator Instructrions) Please note that the chat will not be monitored for any questions to the management. I now hand the conference over to Richard Perrial.
Thank you.
'-
Thank you, Aishwarya. Good morning, good evening, and a warm welcome to all. Thank you for joining us for Dr. Reddy's Q1 FY '26 earnings conference call. We truly appreciate your time and participation. Joining us today are members of the leadership team, Mr. Erez Israeli, our CEO; Mr. MV Narasimham, our CFO; and the IR team.
Earlier today, we released our quarterly financial results. These are now available on our website for your reference. We'll begin the session with MVN presenting an overview of the financial performance for the quarter. Following that, Erez will provide his perspective on the business
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
